Interventional Cardiologist; Director of Cardiology; Director of Cardiac Catheterisation Labs and Coronary Intervention; Associate Professor in VIC


Professor Rob Whitbourn is an Interventional Cardiologist. He is the Director of Cardiac Catheterization Laboratories at St Vincent’s Hospital and Director of Cardiology at St Vincent’s Private Hospital Melbourne

He is a Fellow of the Cardiac Society of Australia and New Zealand and an internationally recognised leader in Interventional Cardiology and novel devices. His research career spans over 20 years, including 2 years as an In Read More...

Procedures & Conditions

Procedures Performed
  • Transcatheter Aortic Valve Intervention (TAVI)
  • Renal Sympathetic Denervation (RDN)
  • Coronary Angiography
  • Coronary Angioplasty/Stenting
  • Laser Percutaneous Myocardial Revascularization (PMR)
  • Coronary Rotablation
  • Intravascular Ultrasound
  • Temporary Pacemaker
  • Intra-Aortic Balloon Pump
  • Pericardial Catheter Insertion
Conditions Treated
  • Aortic Stenosis
  • Resistant Hypertension
  • Coronary Artery Disease


  • Director of Cardiac Catheterisation Labs and Coronary Intervention
    St Vincent's Hospital Melbourne Present
  • Director of Cardiology
    St Vincent's Private Melbourne, Room: 33/141 Grey Street, East Melbourne, 3002 Present
  • Associate Professor
    University of Melbourne Present
  • Department of Medicine
    St Vincent's Hospital Melbourne Present
  • Adjunct Professor
    Australian Catholic University Present
  • Director of Coronary Care
    St Vincent's Hospital Melbourne 1998 - 2007


Professional Memberships and Affiliations
  • 2017 - Present

    Chair of the Publications committee, Australian Cardiac Outcomes Registry

  • 2005 - Present

    Member of the Medical Defence Association of Melbourne

  • 2003 - Present

    Member of the Asia-Pacific Society of Interventional Cardiology

  • 1988 - Present

    Member of the Australian Medical Association

  • 2010

    Chair of the Data Safety Monitoring Board for Plus-One Study

  • 2007 - 2008

    Executive Member of the Australian and New Zealand Endovascular Therapies Meeting

  • 2001 - 2004

    CSANZ Representative CCU Standards Working Party

  • 2001 - 2004

    Advisor of the Victorian Government Ministerial Emergency and Critical Care Committee

  • 1997

    Fellow of the Cardiac Society of Australia and New Zealand

  • 1995

    Fellow of the Royal Australasian College of Physicians

  • 1991, 2001, 2002

    Senior Investigator Award, SVHM Research Week

Research & Publications


1. Adams H, Paratz E, Somaratne J, Layland J, Burns A, Palmer S, MacIsaac A, Whitbourn R. Different patients, different outcomes: A case-control study of spontaneous coronary artery dissection versus acute coronary syndrome. J Interv Cardiol. 2017 Sep 20. doi: 10.1111/joic.12447. [Epub ahead of print]

2. Onuma Y, Grundeken MJ, Nakatani S, Asano T, Sotomi Y, Foin N, Ng J, Okamura T, Wykrzykowska JJ, de Winter RJ, van Geuns RJ, Koolen J, Christiansen E, Whitbourn R, McClean D, Smits P, Windecker S, Ormiston JA, Serruys PW. Serial 5-Year Evaluation of Side Branches Jailed by Bioresorbable Vascular Scaffolds Using 3-Dimensional Optical Coherence Tomography: Insights From the ABSORB Cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). Circ Cardiovasc Interv. 2017 Sep;10(9). pii: e004393. doi: 10.1161/CIRCINTERVENTIONS.116.004393.

3. Ali ZA, Brinton TJ, Hill JM, Maehara A, Matsumura M, Karimi Galougahi K, Illindala U, Götberg M, Whitbourn R, Van Mieghem N, Meredith IT, Di Mario C, Fajadet J. Optical Coherence Tomography Characterization of Coronary Lithoplasty for Treatment of Calcified Lesions: First Description. JACC Cardiovasc Imaging. 2017 Aug;10(8):897-906. doi: 10.1016/j.jcmg.2017.05.012.

4. Worthley SG, Wilkins GT, Webster MW, Montarello JK, Delacroix S, Whitbourn RJ, Warren RJ. Safety and performance of the second generation EnligHTN™ Renal Denervation System in patients with drug-resistant, uncontrolled hypertension. Atherosclerosis. 2017 Jul;262:94-100. doi: 10.1016/j.atherosclerosis.2017.04.022. Epub 2017 May 3.

5. Campos CM, Caixeta A, Franken M, Bartorelli AL, Whitbourn RJ, Wu CJ, Li Paul Kao H, Rosli MA, Carrie D, De Bruyne B, Stone GW, Serruys PW, Abizaid A; ABSORB Cohort B and the SPIRIT II, III, and IV Investigators. Risk and timing of clinical events according to diabetic status of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting stent: 2-year results from a propensity score matched comparison of ABSORB EXTEND and SPIRIT trials. Catheter Cardiovasc Interv. 2017 May 4. doi: 10.1002/ccd.27109. [Epub ahead of print]

6. de Ribamar Costa J Jr, Abizaid A, Bartorelli AL, Whitbourn R, Jepson N, Perin M, Steinwender C, Stuteville M, Ediebah D, Sudhir K, Serruys PW. One-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a propensity score comparison of patients enrolled in the ABSORB EXTEND and SPIRIT trials. EuroIntervention. 2016 Nov 20;12(10):1255-1262.

7. Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L; DAPT Study Investigators. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016 Apr 26;315(16):1735-49. doi: 10.1001/jama.2016.3775. Erratum in: JAMA. 2016 Jul 19;316(3):350. JAMA. 2016 Jul 19;316(3):350.

8. Zweng I, Shi WY, Palmer S, MacIsaac A, Whitbourn R, Davis P, Newcomb AE. Transcatheter versus Surgical Aortic Valve Replacement in High-risk Patients: A propensity-score matched analysis. Heart Lung Circ. 2016 Jul;25(7):661-7. doi: Curriculum Vitae: Robert Whitbourn Page 8 of 26 10.1016/j.hlc.2016.01.005. Epub 2016 Feb 11.

9. Serruys PW, Ormiston J, van Geuns RJ, de Bruyne B, Dudek D, Christiansen E, Chevalier B, Smits P, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Wasungu L, Ediebah D, Veldhof S, Onuma Y. A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis: 5-Year Follow-Up. J Am Coll Cardiol. 2016 Feb 23;67(7):766-76

10. Meredith IT, Walters DL, Dumonteil N, Worthley SG, Tchétché D, Manoharan G, Blackman DJ, Rioufol G, Hildick-Smith D, Whitbourn RJ, Lefèvre T, Lange R, Müller R, Redwood S, Feldman TE, Allocco DJ, Dawkins KD. 1-Year Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients With Severe Aortic Stenosis: Results of the REPRISE II Study. JACC Cardiovasc Interv. 2016 Feb 22;9(4):376-384.

11. Edward KL, Stephenson J, Giandinoto JA, Wilson A, Whitbourn R, Gutman J, Newcomb A. An Australian longitudinal pilot study examining health determinants of cardiac outcomes 12 months post percutaneous coronary intervention. BMC Cardiovasc Disord. 2016 Feb 3;16:31.

12. Palmer S, Layland J, Carrick D, Williams PD, Judkins C, Gong FF, Burns AT, Whitbourn RJ, MacIsaac AI, Wilson AM. The Index of Microcirculatory Resistance Postpercutaneous Coronary Intervention Predicts Left Ventricular Recovery in Patients With Thrombolyzed ST-Segment Elevation Myocardial Infarction. J Interv Cardiol. 2016 Apr;29(2):146-54. Epub 2016 Jan 29.

13. Ishibashi Y, Nakatani S, Sotomi Y, Suwannasom P, Grundeken MJ, Garcia-Garcia HM, Bartorelli AL, Whitbourn R, Chevalier B, Abizaid A, Ormiston JA, Rapoza RJ, Veldhof S, Onuma Y, Serruys PW. Relation Between Bioresorbable Scaffold Sizing Using QCA-Dmax and Clinical Outcomes at 1 Year in 1,232 Patients From 3 Study Cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II). JACC Cardiovasc Interv. 2015 Nov;8(13):1715-26.

14. Mahfoud F, Tunev S, Ewen S, Cremers B, Ruwart J, Schulz-Jander D, Linz D, Davies J, Kandzari DE, Whitbourn R, Böhm M, Melder RJ. Impact of Lesion Placement on Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation. J Am Coll Cardiol. 2015 Oct 20;66(16):1766-1775.

15. Worthley S, Hendriks R, Worthley M, Whelan A, Walters DL, Whitbourn R, Meredith I. Paclitaxel-eluting balloon and everolimus-eluting stent for provisional stenting of coronary bifurcations: 12-month results of the multicenter BIOLUX-I study. Cardiovasc Revasc Med. 2015 Oct-Nov;16(7):413-7.

16. Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, Stone GW; ABSORB III Investigators. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. N Engl J Med. 2015 Nov 12;373(20):1905-15.

17. Stub D, Smith K, Bernard S, Nehme Z, Stephenson M, Bray JE, Cameron P, Barger B, Ellims AH, Taylor AJ, Meredith IT, Kaye DM; AVOID Investigators. Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction. Circulation. 2015 Jun 16;131(24):2143-50. Curriculum Vitae: Robert Whitbourn Page 9 of 26

18. Whitbourn R, Harding SA, Walton A. Symplicity multi-electrode radiofrequency renal denervation system feasibility study. EuroIntervention. 2015 May;11(1):104-9.

19. Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L; Dual Antiplatelet Therapy (DAPT) Study Investigators. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. JAMA. 2015 Mar 17;313(11):1113-21. doi: 10.1001/jama.2015.1671. Erratum in: JAMA. 2016 Jul 5;316(1):105. JAMA. 2016 Jul 5;316(1):105. JAMA. 2015 Jun 2;313(21):2185.

20. De Ribamar Costa J Jr, Abizaid A, Bartorelli AL, Whitbourn R, van Geuns RJ, Chevalier B, Perin M, Seth A, Botelho R, Serruys PW; ABSORB EXTEND Investigators. Impact of post-dilation on the acute and one-year clinical outcomes of a large cohort of patients treated solely with the Absorb Bioresorbable Vascular Scaffold. EuroIntervention. 2015 Jun;11(2):141-8.

21. Hermiller JB, Leimbach W, Gammon R, Karas SP, Whitbourn RJ, Wong SC, Goswami N, McCabe J, Cavros NG, Paulus R, Naidu SS, Turi ZG. A prospective, randomized, pivotal trial of a novel extravascular collagen-based closure device compared to manual compression in diagnostic and interventional patients. J Invasive Cardiol. 2015 Mar;27(3):129-36

22. Böhm M, Mahfoud F, Ukena C, Hoppe UC, Narkiewicz K, Negoita M, Ruilope L, Schlaich MP, Schmieder RE, Whitbourn R, Williams B, Zeymer U, Zirlik A, Mancia G; GSR Investigators. First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension. 2015 Apr;65(4):766-74.

23. Onuma Y, Serruys PW, Muramatsu T, Nakatani S, van Geuns RJ, de Bruyne B, Dudek D, Christiansen E, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Garcia-Garcia HM, Veldhof S, Rapoza R, Ormiston JA. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2014 Dec;7(12):1400-11.

24. Ngan C, Tsai YC, Palasubramaniam D, Wilson-O’Brien A, Layland J, Whitbourn R, Wilson A. Diabetes and poor glycaemic control in rural patients with coronary artery disease. Int J Cardiol. 2015 Feb 1;180:264-9.

25. Williams PD, Palmer S, Judkins C, Gutman J, Whitbourn R, MacIsaac A, Xu B, Burns A, Wilson A. Right and left heart catheterization via an antecubital fossa vein and the radial artery–a prospective study. J Invasive Cardiol. 2014 Dec;26(12):669-73 Curriculum Vitae: Robert Whitbourn Page 10 of 26.

26. Meredith IT, Walton A, Walters DL, Pasupati S, Muller DW, Worthley SG, Yong G, Whitbourn R, Duffy SJ, Ormiston J. Mid-term outcomes in patients following transcatheter aortic valve implantation in the CoreValve Australia and New Zealand Study. Heart Lung Circ. 2015 Mar;24(3):281-90.

27. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014 Dec 4;371(23):2155-66.

28. Gillespie J, Walton T, Schlaich M, Whitbourn R, Krum H, McBride M. Prevalence of Severe Treatment Resistant Hypertension and Eligibility for Catheter-Based Renal Denervation in Australia – a Preliminary Analysis. Value Health. 2014 Nov;17(7):A759.

29. Tilden D, McBride M, Whitbourn R, Krum H, Walton T, Gillespie J. Cost Effectiveness of Catheter-Based Renal Denervation for Treatment Resistant Hypertension – an Australian Payer Perspective. Value Health. 2014 Nov;17(7):A762.

30. McBride M, Krum H, Schlaich M, Whitbourn R, Walton T, Tilden D, Gillespie J. Effectiveness of Catheter-Based Renal Denervation for Treatment Resistant Hypertension – Results of a Systematic Review and Meta-Analysis. Value Health. 2014 Nov;17(7):A757-8.

More research publications available upon request. 

View More

Related Articles

LATEST IN Accredited TAVI Practitioner

Heart valve disease (HVD) is a significant health issue in…

LATEST IN Accredited TAVI Practitioner

Mitral Valve Regurgitation (MVR) is the most common valvular abnormality…

LATEST IN Accredited TAVI Practitioner

What is Chest Pain? Chest pain describes a feeling of…